Navigation Links
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
Date:5/22/2008

enics Pharmaceuticals, Inc. "We await results within the coming months from a second, ongoing phase 2 study involving the oral formulation of RELISTOR that was announced last July to have positive activity in a phase 1 trial."

RELISTOR Intravenous Formulation

The Progenics-conducted phase 3 study of an intravenous formulation of RELISTOR for patients with post-operative ileus (POI) did not meet the primary or secondary end points, confirming the earlier findings of the Wyeth phase 3 intravenous POI study announced on March 12, 2008. Progenics and Wyeth will now study the results of both phase 3 intravenous POI studies to determine whether and how to continue development of this formulation of RELISTOR and this indication.

RELISTOR Franchise

"We are committed to continuing to develop the RELISTOR franchise to help address the unmet medical needs of patients suffering from the gastrointestinal side effects of opioids. Following the results from a second phase 2 clinical trial of another oral formulation, Wyeth and Progenics will further define the continued development plan for oral RELISTOR," says Gary L. Stiles, M.D., Executive Vice President, Chief Medical Officer, Wyeth Pharmaceuticals.

About RELISTOR and Opioids

RELISTOR is a peripherally acting mu-opioid receptor antagonist that counteracts the constipating effects of opioid pain medications in the gastrointestinal tract without affecting their ability to relieve pain.

Opioids provide pain relief by specifically interacting with mu-opioid receptors within the central nervous system (CNS) -- the brain and spinal cord. However, opioids also interact with mu-opioid receptors found outside the CNS, such as those within the gastrointestinal tract, resulting in constipation that can be debilitating. RELISTOR selectively displaces opioids from the mu-opioid receptors outside the CNS, including those located in the gastrointestinal tract, thereby decreasing their constipa
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Calif. , Sept. 2, 2014 Depomed, ... it intends to offer, subject to market and other ... Notes due 2021 (the "Notes"). Depomed, Inc. ("Depomed") expects ... option to purchase up to an additional $34.5 million ... Co. LLC and RBC Capital Markets, LLC will act ...
(Date:9/2/2014)...  XBiotech announced today interim results from its ... US for its anti-cancer agent Xilonix™. ... being evaluated in advanced colorectal cancer patients where ... endpoint of the study is overall survival, comparing ... population provided only palliative therapy for cachexia. ...
(Date:9/2/2014)... September 2, 2014 According ... Market Research "Latin America Home Healthcare Market (By ... Healthcare Devices, Mobility Assist Devices and Medical Supplies; ... Infusion Therapy and Unskilled Home Healthcare Services) - ... 2014 - 2020" the Latin American Home Healthcare ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6
... , , SALT LAKE CITY , ... Heart Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory ...  the Company  received a NASDAQ Staff Deficiency Letter indicating that ... This Rule requires the Company to have at least three ...
... , BOSTON , Feb 5 ... to announce the Company has signed an agreement with Expert ... Company,s ISO 13485 quality management system (QMS) initiative. Expert Resource ... Endoscopy to create a quality management system that meets the ...
Cached Medicine Technology:NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative 2
(Date:9/2/2014)... September 03, 2014 Recently, Top ... hosting companies and announced that JustHost ( http://www.justhost.com/track/seohosts ... the webmasters. , “The hosting suppliers we recommend ... their competitors on hosting features, uptime and server ... 10 Best SEO Hosting says. “We believe that ...
(Date:9/2/2014)... 02, 2014 The use of Xarelto ... is growing at a rapid pace, even as ... courts around the U.S., Bernstein Liebhard LLP reports. According ... Medicine, within a year of its 2011 launch, patients ... warfarin, a blood thinner that has been in use ...
(Date:9/2/2014)... breast cancer in California, the percentage undergoing a double ... procedure was not associated with a lower risk of ... study in the September 3 issue of JAMA ... removal of one breast was associated with a higher ... the study. , Randomized trials have demonstrated similar survival ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey Bar and Grill ... Cord Injury Awareness Month featuring full band performances by Zane ... Automotive will be there hosting a Hot Rod, Rat Rod, ... The car show is Pre 1964 only, with a $50.00 ... There will be trophies for top 3 and best of ...
(Date:9/2/2014)... supplements did not reduce delirium in seniors who had ... Many older hospital patients experience the sudden, severe confusion ... sleep-wake cycle. A lack of the hormone melatonin may ... has been little research into whether melatonin supplements would ... average age 84, who had hip fracture surgery. About ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... HEIGHTS, N.J., May 2 Authentidate,Holding Corp. (Nasdaq: ... workflow,management software and web-based services, today announced the ... on Friday, May 2,2008, at the Grand Hyatt ... election of the following individuals to,serve on Authentidate,s ...
... Inc.,(Nasdaq: OSTE ) announces today that on April ... response to its notification to Nasdaq that,Robert W. Gunn, ... of,Directors, Audit and Compensation Committees, passed away unexpectedly on,April ... independent directors,serving on its Audit Committee and is not ...
... ATLANTA, May 2 Now in its 11th year ... cancer research, Georgia Power,s Run for,the Reason relay team ... and support the American Cancer Society. This year,s relay ... Georgia Power president and,CEO who passed away from cancer ...
... On the eve of the British Columbia inquiry into the ... CMAJ (Canadian Medical Association Journal) finds that in some cases, ... evidence is contrary to current views that stun guns only ... the pulses generated by stun guns are designed to incapacitate ...
... Properties, Inc.,s (NYSE: NHP ) Board of Directors declared ... that will be paid on,June 6, 2008 to shareholders of ... of Directors declared cash dividends of,$1.9375 per share on its ... be paid on June 30, 2008 to stockholders of,record on ...
... 2 Hill-Rom Holdings,Inc., (NYSE: HRC ) invites ... president and chief executive officer, Hill-Rom. He will be,speaking ... Las Vegas on,Thursday, May 15, 2008 at 9:10 a.m. ... listen to the live presentation via the internet,link at ...
Cached Medicine News:Health News:Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders 2Health News:Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders 3Health News:Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter 2Health News:Relay Team Runs to Raise Funds for the American Cancer Society 2Health News:Evidence that stun guns may stimulate the heart 2Health News:NHP Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 2Health News:NHP Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: